IOBCF (Ion Beam Applications) ROCE %: 16.42% (As of Dec. 2025)


IOBCF Ion Beam Applications SA IOBCF
82 GF Score
Price $18.50
GF Value $18.71
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Ion Beam Applications ROCE %?

Ion Beam Applications IOBCF 82 ROCE % is 16.42% as of Dec. 2025. GuruFocus rates IOBCF with a GF Score™ of 82/100 and a GF Value™ of $18.71 (Fairly Valued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ion Beam Applications's annualized ROCE % for the quarter that ended in Dec. 2025 was 16.42%.

Ion Beam Applications  (OTCPK:IOBCF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ion Beam Applications ROCE % Related Terms

Ion Beam Applications ROCE % Historical Data

* Premium members only.

The historical data trend for Ion Beam Applications's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ion Beam Applications ROCE % Chart

Ion Beam Applications Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.78 0.87 1.14 11.45 13.05

Ion Beam Applications Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.11 -2.70 27.06 10.64 16.42
IOBCF
82GF Score
Ion Beam Applications SA IOBCF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ion Beam Applications ROCE % Calculation

Ion Beam Applications's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=26.691/( ( (645.177 - 491.103) + (808.628 - 553.521) )/ 2 )
=26.691/( (154.074+255.107)/ 2 )
=26.691/204.5905
=13.05 %

Ion Beam Applications's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=35.494/( ( (723.171 - 546.054) + (808.628 - 553.521) )/ 2 )
=35.494/( ( 177.117 + 255.107 )/ 2 )
=35.494/216.112
=16.42 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.42% mean?
Ion Beam Applications (IOBCF) has a ROCE % of 16.42% as of Dec. 2025.
Is Ion Beam Applications' ROCE % too high?
Ion Beam Applications' current ROCE % is 16.42%. The Medical Devices & Instruments industry median ROCE % is 2.23. Ion Beam Applications' value of 16.42% is 636.3% above this industry median. Overall, Ion Beam Applications has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' ROCE % compare to ABT and SYK?
Ion Beam Applications' ROCE % of 16.42% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Ion Beam Applications' value of 16.42% is 636.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current ROCE % of 16.42% is 636.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current ROCE % is 16.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.71, compared to a current price of $18.50 — trading 1.1% below its estimated fair value. The current ROCE % is 16.42% and 636.3% above the Medical Devices & Instruments industry median of 2.23. Ion Beam Applications' overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current ROCE % is 16.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ion Beam Applications (IOBCF) Overvalued in 2026?

Based on GuruFocus' analysis, Ion Beam Applications stock appears to be undervalued. The current stock price of $18.50 is trading 1.1% below its estimated GF Value™ of $18.71. GuruFocus considers Ion Beam Applications to be Fairly Valued.

Key valuation signals for IOBCF:

  • ROCE %: 16.42%
  • GF Value™: $18.71 vs. price of $18.50 (1.1% below fair value)
  • GF Score™: 82/100 with 10 warning signs
  • Industry Position: 636.3% above the Medical Devices & Instruments median

No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ion Beam Applications Business Description

Address Chemin du Cyclotron, 3, Louvain-La-Neuve, BEL, B-1348
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
82GF Score

Get the complete analysis for IOBCF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.50
Price
$18.71
GF Value